Search

Draeger Atlan A350 and A350 XL Anesthesia Workstation Correction

FDA classified Draeger Atlan A350 and A350 XL anesthesia workstations as a Class I recall—the most serious type—due to potential piston ventilator failure before or during use. Draeger is instructing customers to inspect and, if necessary, replace the ventilator motor assembly. Healthcare providers may continue using affected devices under permanent supervision until the corrective action is implemented.

US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD

The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.

Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics

USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.

Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells

USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.

US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS

The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.

Tricyclic KRAS Inhibitor Patent - Incyte Corporation

The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.

Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation

USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.

Viral and Non-Viral Nanoplasmid Vectors with Improved Production

USPTO granted patent US12600984B2 to Aldevron, L.L.C. covering methods for improving replication of covalently closed circular plasmids through replacement of Pol I-dependent origins with Pol III-dependent origins. The patent also claims antibiotic marker free covalently closed circular recombinant DNA molecules. The patent contains 31 claims.

Modified Double-Stranded Oligonucleotide Patent - Alnylam Pharmaceuticals

USPTO granted patent US12600965B2 to Alnylam Pharmaceuticals, Inc. covering modified double-stranded RNA (dsRNA) agents capable of inhibiting target gene expression. The patent, filed November 5, 2019, includes 38 claims and covers pharmaceutical compositions comprising these dsRNA molecules for therapeutic applications. Inventors include Donald Foster, Mark K. Schlegel, and Christopher Brown.

Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr

Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr